The Medical Advisor

By Dr. Frank Yap, MD · Published 2026-10-05 · Last updated 2026-10-05 · Reading time about 10 minutes Quick Answer Ozempic and Wegovy are both semaglutide; Mounjaro is tirzepatide. Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy is labeled for weight management (Mounjaro's weight-management sibling is Zepbound). In the SURPASS-2 diabetes trial, tirzepatide lowered A1C and body weight more than semaglutide 1 mg over 40 weeks. The best fit depends on diagnosis, heart and kidney history, tolerability and cost. In this article What is each medicine and what is it approved for? Ozempic vs Wegovy: same molecule, what changes? Ozempic vs Mounjaro: what does the head-to-head trial show? Wegovy vs Mounjaro: which is better for weight loss? Three-...

Updated October 2026 · This article focuses on the weekly injectable products. U.S. FDA indications are used for the regulatory comparison; availability, brand names, dosing and approvals can differ in Malaysia and other countries. Ozempic, Wegovy, Mounjaro and Trulicity are not simply four versions of the same drug. Ozempic and Wegovy contain semaglutide; Mounjaro contains tirzepatide; and Trulicity contains dulaglutide. The most important pharmacologic difference is that tirzepatide activates both GIP and GLP-1 receptors , whereas the other three are GLP-1 receptor agonists. For weight loss, the 2026 picture is more nuanced than it was a few years ago. Tirzepatide has produced greater average weight loss than semaglutide in a direct head-to-head obesity trial. At the same time, semaglutide has moved into a new phase with Wegovy HD 7.2 mg , approved by the U.S. FDA in March 2026 for additional weight reduction in appropriate adults. Bottom line: For obesity treatment, ...

Introduction Cancers of the female reproductive system, including ovarian, endometrial (uterine), and cervical cancers, represent a significant global health burden, often presenting at advanced stages with limited treatment options and poor prognosis. Conventional therapies such as chemotherapy, radiation, and surgery, while effective in some cases, frequently fail in recurrent or metastatic disease, prompting exploration of drug repurposing strategies.  This compilation examines emerging case reports on the off-label use of antiparasitic agents—primarily ivermectin and fenbendazole, alongside related benzimidazoles like mebendazole—in managing these malignancies. Drawing from 19 documented cases, the article categorizes outcomes by cancer type and integrates mechanistic insights from preclinical studies, where these compounds have demonstrated antitumor effects such as microtubule disruption, inhibition of oncogenic signaling pathways (e.g., PAK1, Wnt/β-catenin), induction of apo...